Esperion Therapeutics | ESPR - Gross Profit On Sales


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Esperion Therapeutics

Esperion Therapeutics reported $12.68M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.


Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US USD 264.42M 19.35M
Amgen AMGN:US USD 4.42B 669M
Biogen BIIB:US USD 1.8B 172.9M
BioMarin Pharmaceutical BMRN:US USD 469.87M 59.62M
Daiichi Sankyo 4568:JP JPY 224.22B 18.28B
Eli Lilly LLY:US USD 5.33B 420.4M
Esperion Therapeutics ESPR:US USD 12.68M 1.98M
Halozyme Therapeutics HALO:US USD 126.97M 12.4M
Intercept Pharmaceuticals ICPT:US USD 67.74M 9.46M
Intra Cellular Therapies ITCI:US USD 88.56M 7.47M
Ionis Pharmaceuticals IONS:US USD 129.18M 19.02M
Merck & Co MRK:US USD 11.14B 1.15B
Moderna Inc MRNA:US USD 1.07B 2.1B
Nektar Therapeutics NKTR:US USD 14.53M 1.26M
Pfizer PFE:US USD 13.26B 1.21B
PTC Therapeutics PTCT:US USD 206.24M 49.72M
Puma Biotechnology PBYI:US USD 39.56M 9.28M
Regeneron Pharmaceuticals REGN:US USD 2.7B 169.2M
Sarepta Therapeutics SRPT:US USD 218.48M 9.14M
Seattle Genetics SGEN:US USD 407.94M 12M
United Therapeutics UTHR:US USD 454.6M 21.9M